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Abstract: Timely treatment of thyroid disease during pregnancy is important in preventing 
adverse maternal and fetal outcomes. Thyroid abnormalities are very often subclinical in nature 
and not easily recognized without specific screening programs. Even mild maternal thyroid hor-
mone deficiency may lead to neurodevelopment complications in the fetus. The main diagnostic 
indicator of thyroid disease is the measurement of serum thyroid-stimulating hormone and free 
thyroxine levels. Availability of gestation-age-specific thyroid-stimulating hormone thresholds is 
an important aid in the accurate diagnosis and treatment of thyroid dysfunction.   Pregnancy-specific 
free thyroxine thresholds not presently available are also required. Large-scale intervention   trials 
are urgently needed to assess the efficacy of preconception or early pregnancy screening for thyroid 
disorders. Accurate interpretation of both antepartum and postpartum levels of thyroid hormones 
is important in preventing pregnancy-related complication secondary to thyroid dysfunction. This 
article sheds light on the best ways of management of thyroid dysfunction during pregnancy in 
order to prevent any possible maternal or fetal complication.
Keywords: TSH, HCG, TBG
Introduction
It is a very well known fact that thyroid diseases during pregnancy are related to mater-
nal and fetal complications. In this article, the authors try to summarize the possible 
adverse outcomes of hypothyroidism and hyperthyroidism on the mother and fetus 
during gestation. They also shed light on the proper management of these conditions 
to avoid such complications.
Physiology of maternal thyroid in pregnancy
The thyroid gland undergoes definite physiological changes during pregnancy. 
  Moderate thyroid enlargement and increased vascularity occurs as a result of pregnancy 
hormone-induced glandular hyperplasia. Thyroid stimulation starts as early as the 
first trimester by human chorionic gonadotropin hormone (beta-HCG), which shares 
some structural homology with thyroid-stimulating hormone (TSH). There is also an 
estrogen-mediated increase in circulating levels of thyroid-binding globulin (TBG). 
Furthermore, there is a relative decline in the availability of iodide, secondary to the 
increased renal clearance and overall losses to fetus and placenta.1
Circulating TBG is known to increase 2–3-fold during pregnancy. Serum TBG 
increases a few weeks after conception and reaches a plateau during mid-gestation. 
The mechanism behind this increase involves increased hepatic synthesis and estrogen-
mediated prolongation of TBG half-life from 15 minutes to 3 days.2
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Total thyroxine (T4) and total triiodothyronine (T3) 
  concentrations increase sharply in early pregnancy and 
plateau early in the second trimester at concentrations 
30%–100% greater than prepregnancy values, primarily 
following the rise in TBG. However changes in free T4 and 
T3 concentrations during pregnancy are controversial. Some 
authors have reported a decrease in free hormones, whereas 
others have reported no change or even an increase. Pregnant 
women in general have lower free-hormone concentrations 
at term than nonpregnant women.3–5
Beta-HCG has a mild thyrotropic activity and shares 
85% sequence homology with TSH beta subunit. During 
the first trimester of pregnancy, beta-HCG is at its   greatest 
  concentration, while serum TSH drops. Thyroglobulin 
  frequently increases during pregnancy reflecting an increased 
activity of the thyroid gland.6
The physiology of fetal thyroid
The fetal thyroid gland begins concentrating iodine and 
  synthesizing thyroid hormones after 12 weeks of gestation. 
Any requirement for thyroid hormones before this time is 
solely supplied by the mother. It is during the first trimester 
of pregnancy that the thyroid hormones are most important to 
fetal brain development. Still, significant fetal brain develop-
ment continues considerably beyond the first trimester,   making 
thyroid hormones important also later in gestation. Overt 
maternal thyroid failure during the first half of pregnancy has 
been associated with several pregnancy complications and 
intellectual impairment in the offspring. It is currently less 
clear whether milder forms of thyroid dysfunction have similar 
effects on pregnancy and infant outcomes.7,8
Hypothyroidism
Untreated hypothyroidism is associated with pregnancy-
  induced hypertension, abruption, and postpartum hemor-
rhage plus an increase in frequency of low birth weight 
infants. Mild or subclinical hypothyroidism has been 
reported to increase the risk of impaired neurodevelop-
ment in the offspring.9–12 Hypothyroidism occurs in 2.5% 
of   pregnancies; however, overt hypothyroidism only 
complicates 1–3 per 1000 pregnancies.13 Symptoms of 
hypothyroidism can often be masked by the hypermetabolic 
state of pregnancy. During the early weeks of pregnancy, 
a fall in serum TSH and increase in free thyroxine (FT4) is 
observed that may confuse the diagnosis of hypothyroidism. 
The reference range for serum TSH in nonpregnant women 
is 0.45–4.5 mU/L, with more than 95% of individuals hav-
ing a value below 2.5 mU/L. Gestation-age-specific TSH 
thresholds from large population-based studies seem to be 
the best way to increase diagnostic accuracy of hypothyroid-
ism in pregnancy.14
In an article by Haddow et al, thyrotropin (TSH) 
was   measured in stored serum samples collected from 
25,216 pregnant women. A total of 47 women with serum 
  thyrotropin concentrations at or above the 99.7th percentile 
of the values for all the pregnant women and 15 women with 
values between the 98th and 99.6th percentiles, inclusive, 
in combination with low thyroxine levels, and 124 matched 
women with normal values were located. Their 7–9-year-old 
children, none of whom had hypothyroidism as newborns, 
underwent 15 tests relating to intelligence, attention, 
  language, reading ability, school performance, and visual–
motor performance. The children of the 62 women with 
high serum thyrotropin (hypothyroid group) concentrations 
performed slightly less well on all 15 tests. Their full-scale 
IQ scores on the Wechsler Intelligence Scale for Children, 
third edition, averaged 4 points lower than those of the 
children of the 124 matched control women (P = 0.06, not 
significant). Of these 62 women with thyroid deficiency, 
48 were not treated for the condition during the preg-
nancy. The full-scale IQ scores of their children averaged 
7 points, significantly lower than those of the 124 matched 
control children (P = 0.005). The authors conclude that 
“  undiagnosed hypothyroidism in pregnant women may 
adversely affect their fetuses; therefore screening for thyroid 
deficiency during pregnancy is warranted.”12
Subclinical maternal hypothyroidism may be associated 
with poor pregnancy outcomes such as placental abruption, 
preterm birth, and low birth weight infants. Pregnancies in 
women with subclinical hypothyroidism were three times 
more likely to be complicated by placental abruption. Preterm 
birth, defined as delivery at or before 34 weeks of gesta-
tion, was almost 2-fold higher in women with subclinical 
hypothyroidism. Reports suggesting increased fetal wastage 
or subsequent neurodevelopmental complications in the off-
spring of women with mild hypothyroidism have prompted 
recommendations that levothyroxine be prescribed to restore 
the TSH level to the reference range. However, there are still 
no published intervention trials specifically assessing the 
efficacy of such treatment to improve neuropsychological 
performance in the offspring of women with subclinical 
hypothyroidism. Routine screening and treatment of sub-
clinical hypothyroidism during pregnancy is not yet strictly 
recommended. National endocrinology organizations have 
greatly emphasized the need for large clinical trials to address 
this issue.1,11,15
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Management
Treatment should be initiated as soon as the diagnosis of overt 
hypothyroidism is made. The starting dose of levothyroxine 
is 0.10–0.15 mg/day (1–2 µg/kg/day) and should be adjusted 
every 4 weeks to keep the TSH at the lower end of normal. 
Women who are on levothyroxine at the beginning of preg-
nancy should have their dose increased by approximately 
30% as soon as pregnancy is confirmed and have their TSH 
and free T4 levels checked every 8 weeks. Levothyroxine 
replacement requirements most likely will increase as the 
pregnancy progresses. This increase can be secondary to the 
increased demand for T4 with the progression of pregnancy 
as well as its inadequate intestinal absorption caused by 
accompanied ferrous sulfate replacement in most pregnant 
ladies. Thus levothyroxine and ferrous sulfate dosages should 
be spaced at least 4 hours apart.16
Follow-up after delivery
After delivery, levothyroxine therapy should be returned 
to the prepregnancy dose, and the TSH checked 6–8 weeks 
postpartum. Breastfeeding is not contraindicated in women 
treated for hypothyroidism. Levothyroxine is excreted into 
breast milk, but levels are too low to alter thyroid function 
in the infant or to interfere with neonatal thyroid screening 
programs. Periodic monitoring with an annual serum TSH 
concentration for the mothers is generally recommended.
Hyperthyroidism
Hyperthyroidism is less common than hypothyroidism, as 
it occurs in only 0.2% of pregnancies. Some of the signs 
and symptoms of hyperthyroidism may mimic the nor-
mal physiological changes of pregnancy. Severe maternal 
hyperthyroidism is associated with increased risk of stillbirth, 
preterm delivery, intrauterine growth restriction, preeclamp-
sia, and heart failure. Thyrotoxicosis at conception also 
increases the risk for spontaneous abortion.17
The most common cause of hyperthyroidism in pregnancy 
is Graves’ disease, which constitutes up to 95% of the cases. 
Other causes include gestational trophoblastic disease, toxic 
multinodular goiter or solitary toxic adenoma, and viral 
  thyroiditis. In Graves’ disease, there does not seem to be any 
clinical correlation between the levels of antibody activity 
and disease severity. These antibodies, however, can cross 
the placenta and cause neonatal Graves’ disease.
Gestational transient hyperthyroidism (GTH) is   associated 
with hyperemesis gravidarum, commonly presenting with 
elevated levels of FT4 and suppressed levels of TSH. This 
change is believed to be related to beta-HCG stimulation 
of the thyroid gland. GTH occurs in the first trimester in 
women who do not have a history of autoimmune disease. 
The thyroid gland is usually not enlarged. The resolution of 
symptoms parallels the decline in beta-HCG levels. Patients 
rarely need treatment, but beta blockers can be used for 
symptomatic relief.19,20
Subclinical hyperthyroidism is defined as a serum TSH 
concentration below the lower limit of reference range, with 
free T4 and free T3 concentrations within normal reference 
range. It affects up to 1.7% of pregnant women. Long-term 
adverse consequences may include osteoporosis, cardiovas-
cular morbidity, and progression to overt thyrotoxicosis. 
However, subclinical hyperthyroidism in pregnancy has 
not been found to be associated with adverse outcomes. 
Thus, currently there is insufficient evidence in support of 
treating pregnant women with subclinical hyperthyroidism. 
The potential for long-term adverse sequelae in the mothers 
suggests that these women may benefit from periodic surveil-
lance later in life.1,11
Management
The goal of treatment of hyperthyroidism during preg-
nancy is to keep the patient euthyroid, with the FT4 level 
in the upper limit of normal range so as not to cause fetal 
or   neonatal hypothyroidism. Propylthiouracil (PTU) is the 
drug of choice, but methimazole is also frequently used. 
Both are thionamides, which act by inhibiting the iodination 
of thyroglobulin and preventing thyroglobulin synthesis by 
competing with iodine for the enzyme peroxidase. PTU is 
given in a dose of 100–150 mg/8 hours (300–450 mg/day). 
It may take 2–4 weeks from the start of treatment to see 
a clinical change. Free T4 levels should be monitored 
monthly. After achieving an euthyroid state, the dosage 
of PTU should be tapered to minimize fetal exposure to 
thionamides. If PTU or methimazole are contraindicated, 
beta blockers may be used to control the adrenergic 
symptoms of thyrotoxicosis, particularly tachycardia. In 
addition, beta blockers block the peripheral conversion of 
T4 to T3. Propranolol in a dose of 20–40 mg 2–3 times a 
day is commonly used. In acute cases, intravenous esmolol 
(up to 200 g/kg/minute) may be used to maintain a heart 
rate of less than 90 beats/min. Surgery should be reserved 
for the most severe cases. Radioactive iodine is an abso-
lute contraindication in pregnancy. It is also important to 
continue medications throughout the postpartum period, 
as exacerbation of Graves’ disease is common during this 
time. PTU and methimazole are considered compatible with 
breastfeeding.11,17,18
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Conclusion
It is well documented that thyroid disorders are associated 
with maternal and fetal complications during gestation. This 
present paper has discussed the possible ways to prevent and 
manage these outcomes to assure a safe and proper ending 
to pregnancy.
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